Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 21 to 55

Seeing if CBD reduces the effects of THC

Official title: Interactions Between Delta-9-THC and CBD: A Controlled Human Drug-administration Study Probing a Harm Reduction Strategy

Run by University of California, Los Angeles · NCT06859710 · Data updated 2026-11-12

This trial tests whether different doses of CBD change the effects of THC in adults who regularly use inhaled cannabis.

Quick facts

PhasePhase 1
Study typeInterventional
Ages21 Years to 55 Years
SexAll
Enrollment30 (estimated)
SponsorUniversity of California, Los Angeles
Academic / other
Locations1 site (Los Angeles, California)
StatusRecruiting
StartedNovember 5, 2025
Main results expectedSeptember 1, 2027
Study endsSeptember 1, 2028
Registry record updatedDecember 17, 2025
Trial IDNCT06859710 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 21–55 who inhale cannabis 1–7 days per week, are not seeking treatment for cannabis use, have BMI 18.5–34 kg/m2, are not pregnant or breastfeeding, and agree to use contraception are ideal candidates.

Probably not a fit

People with severe cannabis or other substance use disorders, significant psychiatric illness, recent use of other illicit drugs, pregnant or breastfeeding individuals, or those who infrequently or never use cannabis are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 1, randomized, placebo-controlled human study at UCLA gives adults who use inhaled cannabis single doses of THC with or without one of several doses of oral CBD or placebo to see how CBD modifies THC's effects. Eligible participants are 21–55 years old, use cannabis 1–7 days per week, and meet medical and psychiatric screening criteria. Researchers will collect subjective effect ratings, pain response measures, cognitive and psychiatric assessments, and safety/laboratory monitoring during and after dosing. The protocol compares placebo, THC alone, and THC combined with 20 mg, 40 mg, or 80 mg CBD to characterize dose-related modulation of both adverse and analgesic effects.

Why it matters

Potential benefit: If successful, the approach could reduce THC-related adverse effects while preserving its pain-relieving benefits.

How similar studies have gone: Prior laboratory studies report mixed results—some show CBD can blunt certain subjective and psychotic-like effects of THC, but the evidence is inconsistent and not definitive.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male or non-pregnant and non-lactating females aged 21-55 years
* Report cannabis use 1-7 days per week over the month prior to screening
* Not currently seeking treatment for their cannabis use
* History of inhaled cannabis use
* Have a Body Mass Index from 18.5 - 34 kg/m2
* Able to perform all study procedures
* Must be using a contraceptive (hormonal or barrier methods)

Exclusion Criteria:

* Meeting DSM-V criteria for severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, mild or moderate CUD
* Evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and PI) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent.
* Report using other illicit drugs in the prior 4 weeks
* Current pain
* Pregnancy
* Currently enrolled in another research protocol
* Not using a contraceptive method (hormonal or barrier methods)
* Insensitivity to the cold water stimulus of the Cold Pressor Test
* Any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history.
* Not able to speak and read English

Where it's running

  • UCLA Center for Cannabis and Cannabinoids
    Los Angeles, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.